News & Views

Telix today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating PET imaging for patient selection for rADC therapy. The Company has previously reported final safety data from this study[3].

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging for prostate cancer.  

Telix today announces the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.

Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 22 May 2024.

Telix today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). 

Telix, today announces the completion of the acquisition of radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Telix today announces the completion of the acquisition of IsoTherapeutics.   IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix. The acquisition further enhances Telix’s in-house development capabilities and expands Telix’s United States (U.S.) manufacturing footprint with particular focus on bioconjugation and isotope processing.

Telix's 2024 GM was held on Friday, 5th April 2024 at The Wesley Conference Centre in Sydney, Australia and online.

Telix is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.